Cautionary Note Regarding Forward-looking Statements

• This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future operations, future financial position, future cash flows, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

• You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We are under no obligation (and expressly disclaim any such obligation) to update or revise any forward-looking statement that may be made from time to time, whether as a result of new information, future developments or otherwise.

• Risks and uncertainties for Melinta Therapeutics, Inc. (the “Company”) are more fully described in the Company’s recent filings with the SEC, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2017.
Q1 2018 Earnings Conference Call - Agenda

1. Business Update
   Dan Wechsler, President and CEO

2. Financial Results and Outlook
   Paul Estrem, CFO

3. Conclusion and 2018 Catalysts
   Dan Wechsler, President and CEO
Q1 and YTD Business Highlights

Revenue Growth

- $14.8 million of net revenue* in Q1
  - $11.8 million of net product sales in Q1

Operational Strength

- Sales force cross training complete – new incentive plan in place
- Cost synergies to be achieved earlier than anticipated
- Evaluating BD opportunities to monetize valued portfolio ex-US
- Strong support from existing shareholders to support growth of the company

R&D Progress

- Baxdela CABP trial enrollment ahead of schedule
- Vabomere EU application on target
- CARB-X funding received to support advancement of new antibiotic class
- Strong ECCMID presence with 12 posters & presentations
- Submissions of delafloxacin ongoing in Europe and Latin America

* Excludes $2.7 million BARDA grant funding included in Other Income
Vabomere™: Launch Momentum Continues

- 97 formulary approvals to-date
- 0 formulary rejections to-date
- >35% month-over-month ordering growth YTD
- 50% of accounts reordering

Cumulative Ordering Accounts

Source: Company data
Baxdela™: Off to a Terrific Start

- 115 million patient lives have access
- 90 formulary approvals to-date
- 11 different specialties prescribing for ABSSSI
- >30 additional formulary meetings scheduled

Week-over-week Prescribing Doubled Over Last 8 Weeks

Source: Company data
Orbactiv®: Accelerating Growth Quarter-on-quarter

- 54 new accounts in March
- 70% of volume purchased by the hospital
- >50% demand over Q1 2017

Source: Company data

# of Hospital Accounts Ordering

>30%

Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018

# of New Accounts Ordering

2 or More Boxes/Quarter

~50%

Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018

>30% Quarter-on-quarter Growth

~50% Quarter-on-quarter Growth
Minocin®: Sales Reinvigorated with Vabomere

- Double-digit growth vs. Q1 2017 on a pro forma basis
- Increased level of product growth YTD correlation with launch of Vabomere

Boxes Sold By Quarter

Consistent Quarter-over-quarter Gains;
Early Synergies Reported Alongside Vabomere

Source: Company data
Commercial Efficiency and Optimization Underway
Expands Share of Voice for All Products by 2-3x

Step 1: Launch

Incentive Plan 1

Incentive Plan 2

Orbactiv®
(orbitavancin)
for injection

Minocin®
(minocycline)
for injection

Step 2: Optimize

New Incentive Plan

Orbactiv®
(orbitavancin)
for injection

Minocin®
(minocycline)
for injection
Focused on Accelerating Growth and Cash Flows Through Business Development

1. **Ex-US out-licensing**
   - Support existing partnerships
   - OUS rights for Vabomere, Orbactiv, Minocin
   - Japan rights for Baxdela

2. **Strategic acquisitions / partnerships**
   - Accretive, differentiated anti-infective products
   - Leveragable within established commercial infrastructure

3. **Non-core portfolio optimization**
   - Paths to derive value from non-core assets

4. **Government / non-dilutive partnerships**
   - Government contracts, grants, other non-dilutive arrangements
Melinta is Now Powered by CARB-X

• Agreement supporting development of new antibiotic class called the pyrrolocytosine to treat ESKAPE pathogens

• Melinta will receive initial grant of up to $2.3 million with potential to receive additional $3.9 million to support existing discovery efforts

• Initial goal of selecting lead candidate & completing IND-enabling program
Pipeline and Publications Update

- Pediatric formulation work underway
- EMA centralized review in process; LATAM NDA submissions underway
- Phase 3 CABP enrollment completion: Expected by Q4 2018
- Pediatric study ongoing
- EMA regulatory approval: Expected Q4 2018
- TANGO-1 published; TANGO-2 additional data and potentially publication
- Pediatric study ongoing
- Pre-clinical studies to support IV reformulation - under discussion
- Ongoing discussions with EMA related to regulatory approval pathways
- Phase 2 topical acne vulgaris trial ongoing
- Formulation development initiated for bacterial vaginosis, received QIDP
- Announced CARB-X funding
- First ABSSSI Phase 3 met primary endpoint
- Japan partner Toyama completed enrollment in four studies
- US pediatric trial winding down after evaluation and discussions with BARDA

* Non-core assets
Q1 Financial Results & Guidance

Paul Estrem, Chief Financial Officer
## Q1 2018 Financial Highlights – Strong Start to 2018

<table>
<thead>
<tr>
<th>Metrics (in millions)</th>
<th>GAAP</th>
<th>Adjustment</th>
<th>Non-GAAP</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Net Revenue</td>
<td>$14.8</td>
<td></td>
<td>$14.8</td>
<td>Excludes BARDA grant funding</td>
</tr>
<tr>
<td>- Product</td>
<td>11.8</td>
<td></td>
<td>11.8</td>
<td></td>
</tr>
<tr>
<td>- Contract</td>
<td>3.0</td>
<td></td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>COGS</td>
<td>7.7</td>
<td>(4.7)</td>
<td>3.0</td>
<td>Deal-related amortization</td>
</tr>
<tr>
<td>Total Operating Expenses</td>
<td>$50.8</td>
<td>(4.6)</td>
<td>$46.1</td>
<td></td>
</tr>
<tr>
<td>- R&amp;D</td>
<td>16.1</td>
<td>(0.3)</td>
<td>15.8</td>
<td>Stock comp</td>
</tr>
<tr>
<td>- SG&amp;A</td>
<td>34.6</td>
<td>(4.3)</td>
<td>30.3</td>
<td>Stock comp, M&amp;A-related</td>
</tr>
<tr>
<td>Cash &amp; Cash Equivalents</td>
<td>$91.5</td>
<td></td>
<td>$91.5</td>
<td></td>
</tr>
<tr>
<td>Long-term Debt</td>
<td>$147.8</td>
<td></td>
<td>$147.8</td>
<td></td>
</tr>
<tr>
<td>Common Shares Outstanding</td>
<td>31.4</td>
<td></td>
<td>31.4</td>
<td></td>
</tr>
<tr>
<td>Options, RSUs and Warrants Outstanding</td>
<td>6.1</td>
<td></td>
<td>6.1</td>
<td></td>
</tr>
</tbody>
</table>

Anticipate Orbactiv and Minocin to Achieve Net Sales of $36-40 Million for FY 2018
Closing and Catalysts

Dan Wechsler, President & Chief Executive Officer
Melinta Therapeutics, The Antibiotics Company

**Products**
- Strong Q1 performance from four brands with growing momentum

**Pipeline**
- Achieved key development milestones on or ahead of schedule

**Operational Strength**
- Compelling progress on cost savings and sales cross-training
- Focused on enhancing cash position

**Discovery**
- Secured important partnership with CARB-X to support research initiatives
2018 Future Catalysts

- Execute ex-US partnerships for balance of portfolio
- Execute accretive business development opportunities
- Drive focused publication strategy with 30+ planned
- Continue to drive revenue and cost synergies in 2018 and beyond

- Provide launch updates
- Complete enrollment for Phase 3 CABP study
- Receive country approvals in South & Central America

- Provide launch updates
- EMA regulatory approval, including TANGO-2 data
- TANGO-2 data potential publications

- Progress ESKAPE Program in partnership with CARB-X